|
USA-NJ-TOTOWA Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- A Promising New Drug for Treating Cognitive Decline in Schizophrenia
The Science Behind is playing a crucial role in the neurophysiological screening and monitoring of a phase I clinical trial for a new drug, MDI-26478, developed by Cardiff University’s Medicines Discovery Institute, to treat cognitive decline in schizophrenia
- Case study Multiple stakeholders collaborate efectively to deliver HV . . .
Cardif University MDI-26478 drug is a potential new treatment for schizophrenia developed by the Medicines Discovery Institute (MDI) at the university Our scientists worked with their colleagues at the MDI to design a three-part First in Human study This required us to collaborate with both the Cardif University Brain
- Clinical trial launches for new schizophrenia drug
A potential new treatment for schizophrenia developed by Cardiff University’s Medicines Discovery Institute is entering the first phase of a clinical trial The drug - MDI-26478 – is designed to target specific receptors that play a key role in brain health
- Cardiff University begins study of schizophrenia therapy
The treatment candidate, known as MDI-26478, is a positive allosteric modulator of the AMPA receptor A new schizophrenia drug being developed by Cardiff University’s Medicines Discovery Institute (MDI) has completed the first phase of a phase 1 clinical trial
- Trial for new drug to treat schizophrenia to begin in Wales
The drug - MDI-26478 – is designed to target specific receptors that play a key role in brain health Cognitive decline is a core element of schizophrenia and current treatments fail to treat this effectively
- Study Info - Psychology Studies - Cardiff University
Find out more about our CUBRIC study 'A three-part study to investigate MDI-26478 in healthy volunteers'
- Cardiff University begins a study of schizophrenia therapy
The treatment candidate, known as MDI-26478, is a positive allosteric modulator of the AMPA receptor A new schizophrenia drug being developed by Cardiff University’s Medicines Discovery Institute (MDI) has completed the first phase of phase 1 clinical trial
- First Dose Administered in Phase I Trial of Novel Treatment for . . .
Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel treatment for cognitive impairment associated with schizophrenia and a range of disorders connected with the brain and central nervous system, has commenced in our MHRA Accredited Phase I Unit in South Wales
- Clinical trials - Medicines Discovery Institute - Cardiff University
Cardiff University are running a clinical trial to investigate a new drug, called MDI-26478, developed by the Medicines Discovery Institute for the potential treatment of a range of diseases associated with the brain and central nervous system, including schizophrenia
- CNS Indications - Simbec-Orion
Cardiff University MDI-26478 drug is a potential new treatment for schizophrenia developed by the Medicines Discovery Institute (MDI) at the university Our scientists worked with their colleagues at the MDI to design a three-part First in Human study
|
|